Biosimilars balance reduced cost against nonmedical-switching fear

Two days of discussions in mid-July at a Food and Drug Administration Advisory Committee meeting that judged the merits of two biosimilar agents undergoing agency review highlighted the intrinsic...
Source: Family Practice News - Category: Primary Care Source Type: news